By Fineline Cube 
US-based Viatris (NASDAQ: VTRS) announced positive topline results from the second pivotal Phase III VEGA-3 clinical trial evaluating MR-141 (0.75% phenylephrine ophthalmic solution) for the treatment of presbyopia.
Clinical Trial Outcomes
The VEGA-3 study enrolled 545 patients and successfully met its primary endpoint. At 12 hours post-dose on Day 8, a significantly higher proportion of patients treated with MR-141 achieved ≥15 ETDRS letter improvement (≥3 lines) in distance-corrected near visual acuity (DCNVA) in both eyes, and loss of <5 letters in best-corrected distance visual acuity (BCDVA) compared to placebo (p<0.0001). This benefit was observed as early as 1 hour after the first dose (p=0.0002), demonstrating rapid onset and robust efficacy. Additionally, patient-reported functional benefits were significant at Day 3, Day 8, and Week 6. The safety profile of MR-141 was consistent with previous reports.-Fineline Info & Tech